Blastocystosis (ICD-11: 1A35) - Complete Coding and Diagnostic Guide

1. Introduction

Blastocystosis is an intestinal infection caused by the protozoan Blastocystis, a microscopic parasite that colonizes the human gastrointestinal tract. This microorganism presents unique characteristics among protozoans, with variable morphology and a complex life cycle, making it the subject of scientific debates regarding its true pathogenicity and clinical significance. The global prevalence of this parasite is considerable, being found in fecal samples from populations across all continents, with detection rates that vary significantly among different regions and population groups.

The clinical importance of blastocystosis remains a topic of discussion in the medical community. While some infected patients remain completely asymptomatic, others develop significant gastrointestinal symptoms that impact their quality of life. This clinical variability may be related to different genetic subtypes of the parasite, parasitic load, the host's immune status, and the presence of intestinal coinfections.

From a public health perspective, blastocystosis represents a diagnostic and therapeutic challenge. Transmission occurs primarily through the fecal-oral route, via contaminated water or food, becoming more prevalent in areas with inadequate basic sanitation. However, cases are also documented in populations with access to adequate sanitary infrastructure, suggesting multiple transmission routes.

Correct coding of blastocystosis is fundamental for accurate epidemiological recording, allowing for monitoring of trends, appropriate allocation of resources for diagnosis and treatment, and implementation of evidence-based preventive measures. The appropriate use of the ICD-11 code 1A35 ensures that this condition is adequately documented in medical records, facilitating clinical research, epidemiological studies, and decision-making in public health policies.

2. Correct ICD-11 Code

Code: 1A35

Description: Blastocystosis

Parent category: Intestinal infections caused by protozoa

The code 1A35 in the International Classification of Diseases, 11th Revision (ICD-11), specifically designates infection caused by the protozoan Blastocystis. This code is positioned within the chapter on infectious and parasitic diseases, more specifically in the section dedicated to intestinal infections caused by protozoa.

The hierarchical structure of ICD-11 positions blastocystosis alongside other important intestinal protozoal infections, such as giardiasis, cryptosporidiosis, and amebiasis. This organization facilitates navigation through the coding system and helps healthcare professionals rapidly identify related conditions that may be part of the differential diagnosis.

Code 1A35 should be used when there is laboratory confirmation of the presence of Blastocystis in fecal samples, associated or not with compatible clinical manifestations. It is important to emphasize that this code encompasses both symptomatic and asymptomatic cases when there is a need for documentation of infection, although treatment is generally reserved for symptomatic patients.

Precise coding using 1A35 allows epidemiological traceability of this parasitosis, contributing to more reliable health statistics and enabling comparative studies among different populations and time periods. Furthermore, adequate documentation facilitates clinical follow-up of patients and evaluation of the efficacy of therapeutic and preventive interventions.

3. When to Use This Code

Code 1A35 should be applied in specific clinical situations where there is evidence of Blastocystis infection. Below, we present detailed practical scenarios:

Scenario 1: Patient with Chronic Diarrhea and Parasitological Identification

An adult patient presents with intermittent diarrhea lasting more than four weeks, accompanied by diffuse abdominal discomfort and excessive flatulence. After initial investigation that excluded bacterial, viral, and other common gastrointestinal conditions, parasitological stool examination identifies multiple forms of Blastocystis in different samples. No other pathogens were identified. In this case, code 1A35 is appropriate, as there is correlation between persistent gastrointestinal symptoms and documented presence of the parasite.

Scenario 2: Irritable Bowel Syndrome with Identified Blastocystis

A patient with symptoms compatible with irritable bowel syndrome (alternating diarrhea and constipation, abdominal pain, bloating) undergoes parasitological investigation as part of diagnostic evaluation. The examination identifies Blastocystis in significant concentration. After exclusion of other organic causes and considering that some studies suggest association between this parasite and IBS-like symptoms, code 1A35 can be used to document the presence of the protozoan, especially if there is a decision to initiate antiparasitic treatment.

Scenario 3: Detection in Immunocompromised Patient

A patient using immunosuppressants or with a condition that compromises immunity (transplant recipient, undergoing chemotherapy, with HIV) presents with nonspecific gastrointestinal symptoms. Parasitological investigation reveals presence of Blastocystis. Even if symptoms are mild, documentation with code 1A35 is important, as immunocompromised patients may have greater risk of symptomatic manifestations and require specific follow-up.

Scenario 4: Outbreak Investigation or Epidemiological Screening

In the context of epidemiological investigation following identification of multiple cases of gastrointestinal disease in a closed community (institutions, schools, daycare centers), individuals submitted to parasitological examinations show positivity for Blastocystis. Code 1A35 should be used for all confirmed cases, regardless of symptom presence, to allow adequate epidemiological mapping and implementation of control measures.

Scenario 5: Persistent Gastrointestinal Symptoms After Travel

A patient returns from travel to an area with poor sanitary conditions and develops gastrointestinal symptoms that persist for weeks. After exclusion of other common infectious causes (enteropathogenic bacteria, other parasites), the examination identifies Blastocystis. Code 1A35 is appropriate to document this traveler's diarrhea associated with the protozoan.

Scenario 6: Laboratory Finding in Patient with Compatible Symptoms

A patient with complaints of recurrent abdominal bloating, occasional nausea, and altered bowel habits, without alarm signs, undergoes parasitological examination that identifies Blastocystis in significant quantity, without other pathogens. After clinical discussion regarding possible causal relationship and therapeutic decision, code 1A35 appropriately documents the diagnosis.

4. When NOT to Use This Code

It is fundamental to recognize situations where code 1A35 should not be applied, avoiding coding errors:

Incidental Detection Without Clinical Relevance: When Blastocystis is identified on routine parasitological examination in a completely asymptomatic patient with no gastrointestinal manifestations whatsoever, and there is no intention for treatment or specific follow-up for this condition, coding may not be necessary. The mere presence of the organism without clinical significance does not automatically justify the use of the code.

Presence of Another More Relevant Pathogen: If the patient presents with gastrointestinal symptoms and the examination simultaneously identifies Blastocystis and another recognized pathogenic pathogen (such as Giardia lamblia, Entamoeba histolytica, Salmonella spp., Campylobacter spp.), the primary code should reflect the pathogen most likely responsible for the symptoms. Blastocystis may be coded secondarily only if considered clinically relevant.

Confusion with Other Protozoa: Do not use code 1A35 for infections by other intestinal protozoa. Giardiasis should be coded as 1A31, cryptosporidiosis as 1A32, and infections by Balantidium coli as 1A30. Correct microscopic identification is essential to avoid coding errors.

Gastrointestinal Symptoms of Other Confirmed Etiology: When the patient has an established diagnosis of inflammatory bowel disease, celiac disease, lactose intolerance, or another organic gastrointestinal condition that completely explains the symptoms, the coincidental presence of Blastocystis should not be coded as the primary diagnosis unless there is evidence of significant contribution to the clinical presentation.

False-Positive Result or Contamination: In situations where there is suspicion of laboratory error, sample contamination, or results inconsistent with repeated negative tests, the code should not be applied until adequate confirmation.

5. Step-by-Step Coding Process

Step 1: Assess Diagnostic Criteria

The diagnosis of blastocystosis is primarily based on microscopic identification of the protozoan in fecal samples. Parasitological examination of feces (PEF) is the standard diagnostic method and should be performed on multiple samples (ideally three samples on alternate days) to increase diagnostic sensitivity.

Laboratory confirmation requires visualization of characteristic forms of Blastocystis, which may appear as vacuolar forms (most common), granular, amoeboid, or cystic forms. Fecal concentration techniques increase examination sensitivity. Molecular methods such as PCR can be used in specific contexts for confirmation and subtyping, although they are not routinely necessary for coding.

Clinical-laboratory correlation is essential. Assess whether the patient presents symptoms compatible with intestinal protozoan infection: diarrhea (acute or chronic), abdominal pain, bloating, flatulence, nausea, fatigue, or weight loss. Document symptom duration and intensity.

Perform evaluation to exclude other causes. Consider stool cultures for enteropathogenic bacteria, screening for other parasites, and when indicated, investigation of non-infectious causes of gastrointestinal symptoms. Detailed clinical history, including recent travel, risk exposures, and immunological conditions, is fundamental.

Step 2: Verify Specifiers

ICD-11 does not provide mandatory specifiers for code 1A35, but clinical documentation should include important characteristics:

Severity: Document whether the condition is mild (minimal symptoms, without significant impact on daily activities), moderate (symptoms causing discomfort and some functional limitation), or severe (intense symptoms with significant impact on quality of life, need for hydration or hospitalization).

Duration: Specify whether it is an acute presentation (less than two weeks), subacute (two to four weeks), or chronic (more than four weeks). This information is relevant for therapeutic decisions and prognosis.

Predominant clinical characteristics: Identify the main symptom (predominant diarrhea, predominant abdominal pain, malabsorption syndrome) for better case characterization.

Immunological status: Document whether the patient is immunocompetent or immunocompromised, as this may influence therapeutic approach and follow-up.

Step 3: Differentiate from Other Codes

1A30 - Balantidium coli infections: This infection is caused by a ciliated protozoan, morphologically distinct from Blastocystis. Balantidium coli is significantly larger on microscopic examination, presents characteristic cilia and evident nuclei. Differentiation is based on correct microscopic identification. Clinically, B. coli infections tend to cause more severe presentations, potentially including dysentery and colonic ulcerations.

1A31 - Giardiasis: Caused by Giardia lamblia (also known as G. intestinalis or G. duodenalis), it presents characteristic morphology with "pear" or "teardrop" shape in trophozoites and oval cysts with typical internal structures. Clinically, giardiasis frequently causes watery diarrhea, steatorrhea, abdominal bloating, and weight loss, with symptoms generally more defined than in blastocystosis. Microscopic identification is clearly distinct.

1A32 - Cryptosporidiosis: Caused by protozoans of the genus Cryptosporidium, requires special staining techniques (modified Ziehl-Neelsen, auramine) for identification, as oocysts are very small (4-6 micrometers). Clinically, cryptosporidiosis causes profuse watery diarrhea, especially in immunocompromised individuals, with characteristics distinct from blastocystosis. Laboratory differentiation is based on specific staining techniques.

Step 4: Necessary Documentation

For appropriate coding with 1A35, ensure that the medical record contains:

Complete laboratory result: Examination date, method used, description of parasitic forms identified, quantity/parasitic load when possible
Clinical manifestations: Detailed description of symptoms, duration, intensity, and functional impact
Exclusion of differential diagnoses: Documentation of other tests performed and their negative results
Epidemiological context: Risk exposures, travel, contacts, sanitary conditions
Associated conditions: Comorbidities, immunological status, medications in use
Therapeutic decision: Justification for treatment or observation, prescribed medication if applicable
Follow-up plan: Guidance provided, scheduled reassessment

6. Complete Practical Example

Clinical Case

A 34-year-old female patient, a teacher, seeks medical care with a complaint of recurrent abdominal discomfort for approximately eight weeks. She reports alternating episodes of diarrhea (pasty stools, 3-4 bowel movements daily) and periods of normalization of bowel habits. The condition is accompanied by significant abdominal distension, mainly at the end of the day, excessive flatulence and occasional nausea, without vomiting. She denies fever, blood in stools, significant weight loss or nocturnal symptoms.

In her history, she mentions having traveled to a rural area three months ago, where she consumed untreated spring water. She has no relevant comorbidities, does not use medications regularly and denies recent antibiotic use. On physical examination, she appears in good general condition, well-hydrated, with mildly distended, tympanic abdomen, diffusely tender to superficial palpation, without masses or visceromegaly.

Initial tests were requested including complete blood count (normal), C-reactive protein (normal), thyroid function (normal), celiac disease serology (negative) and parasitological stool examination in three samples. Stool culture was negative for enteropathogenic bacteria. The parasitological stool examination revealed abundant presence of vacuolar forms of Blastocystis in all three samples analyzed, with no identification of other parasites.

Considering the persistence of symptoms, the absence of other identified causes and the consistent presence of the protozoan in multiple samples, the diagnosis of symptomatic blastocystosis was established and specific antiparasitic treatment was prescribed, with guidance on hygienic-dietary measures.

Step-by-Step Coding

Criteria Analysis:

Presence of gastrointestinal symptoms compatible with intestinal protozoan infection (intermittent diarrhea, distension, flatulence, abdominal discomfort)
Laboratory confirmation with identification of Blastocystis in three independent samples
Exclusion of other infectious causes (negative stool culture) and non-infectious causes (normal complementary tests)
Temporal correlation between risk exposure (travel with consumption of untreated water) and symptom onset
Absence of other pathogens that could explain the clinical presentation

Code Selected: 1A35 - Blastocystosis

Complete Justification: The code 1A35 is appropriate in this case because all criteria for diagnosis of symptomatic blastocystosis are present. The patient presents with chronic gastrointestinal symptoms (more than four weeks) that impact her quality of life, with robust parasitological confirmation through multiple positive samples. Appropriate investigation excluded other common causes of similar symptoms, strengthening the hypothesis that Blastocystis is the responsible etiological agent.

The epidemiological history with exposure to potentially contaminated water supports the diagnosis. The decision for antiparasitic treatment reinforces the clinical relevance of the infection in this specific context. Documentation with code 1A35 allows appropriate epidemiological recording, justifies the prescription of antiparasitic medication and facilitates follow-up monitoring of the patient.

Complementary Codes: In this specific case, additional codes are not necessary, as there are no complications, comorbidities relevant to the current condition or need to document specific manifestations requiring separate coding. If the patient presented, for example, significant dehydration requiring intravenous hydration, an additional code for dehydration would be appropriate.

7. Related Codes and Differentiation

Within the Same Category

1A30: Balantidium coli Infections

Use code 1A30 when parasitological examination identifies Balantidium coli, a large ciliated protozoan (50-200 micrometers), easily distinguishable under the microscope by the presence of cilia covering its entire surface and two nuclei (macronucleus and micronucleus). Clinically, B. coli infections frequently cause dysentery with blood and mucus, and may progress with colonic ulcerations. The main difference from 1A35 lies in the microscopic identification of the etiological agent and the generally more severe clinical presentation.

1A31: Giardiasis

Code 1A31 is applied when Giardia lamblia is identified on parasitological examination. Trophozoites present characteristic "pear-shaped" morphology with two nuclei and a ventral adhesion structure, while cysts are oval with 2-4 nuclei. Clinically, giardiasis typically causes abundant watery diarrhea, steatorrhea (fatty stools), marked abdominal distension, and may lead to malabsorption syndrome with significant weight loss. Differentiation from 1A35 is based on specific microscopic identification and the more characteristic clinical pattern.

1A32: Cryptosporidiosis

Use 1A32 when Cryptosporidium oocysts are identified through special staining techniques (modified Ziehl-Neelsen, immunofluorescence). Oocysts are very small (4-6 micrometers), stain red by Ziehl-Neelsen technique, and are alcohol-acid resistant. Clinically, cryptosporidiosis causes profuse watery diarrhea, especially severe in immunocompromised patients, with potential for severe dehydration. The main difference from 1A35 lies in the specific diagnostic method required and the typical severity of the clinical presentation.

Differential Diagnoses

Irritable Bowel Syndrome (IBS): May present with overlapping symptoms (abdominal pain, altered bowel habits, distension), but there is no identification of pathogens. The presence of Blastocystis in a patient with IBS-type symptoms requires careful evaluation of the relevance of the finding.

Other Intestinal Infections: Bacterial infections (salmonellosis, campylobacteriosis) and viral infections (norovirus, rotavirus) generally present with more acute onset and can be differentiated by stool cultures and specific tests.

Inflammatory Bowel Disease: Ulcerative colitis and Crohn's disease present with more systemic manifestations, alterations in inflammatory markers, and characteristic endoscopic findings.

Food Intolerances: Lactose intolerance, non-celiac gluten sensitivity present a clear relationship with ingestion of specific foods and there is no parasitic identification.

8. Differences with ICD-10

In the International Classification of Diseases, 10th Revision (ICD-10), blastocystosis was coded as A07.8 - Other specified intestinal diseases due to protozoa. This code was generic, encompassing various uncommon intestinal protozoan infections that did not have their own specific codes.

The main change in ICD-11 was the assignment of a specific and exclusive code for blastocystosis (1A35), reflecting the growing recognition of the clinical and epidemiological importance of this parasitic infection. This specificity enables:

More precise epidemiological tracking: Allows for specific identification and monitoring of blastocystosis cases, without confusion with other rare intestinal parasitic infections.
Facilitated clinical research: Studies on prevalence, clinical manifestations, and therapeutic efficacy can be conducted with more reliable data.
Recognition of clinical relevance: The creation of a specific code reflects the scientific debate regarding the pathogenicity of Blastocystis and its importance in certain clinical contexts.

The practical impact of these changes includes greater visibility of the condition in health information systems, improved documentation in electronic health records with specific fields for blastocystosis, and potential for development of more standardized clinical guidelines and treatment protocols. For healthcare professionals, the transition requires updating knowledge about the new coding, ensuring that cases previously coded as A07.8 are now appropriately registered as 1A35 when applicable.

9. Frequently Asked Questions

How is blastocystosis diagnosed?

Diagnosis is performed through parasitological stool examination, which identifies characteristic forms of Blastocystis under the microscope. Collection of at least three samples on alternate days is recommended, as parasite shedding in stool may be intermittent. Fecal concentration techniques increase examination sensitivity. In some specialized centers, molecular methods such as PCR can be used for confirmation and subtype identification, although these are not necessary for routine diagnosis. Correlation between laboratory findings and clinical manifestations is essential to determine the relevance of the finding.

Is treatment available in public health systems?

Medications used to treat blastocystosis, such as metronidazole, nitazoxanide, and other antiparasitic agents, are generally available in public health systems, although specific availability may vary between different regions and countries. It is important to consult local protocols and therapeutic formularies to verify availability and approved indications. In many contexts, treatment is reserved for symptomatic patients, as eradication in asymptomatic carriers is not universally recommended.

How long does treatment last?

Treatment duration varies according to the medication used and the protocol adopted. Typically, therapeutic regimens range from 5 to 10 days of continuous treatment. Metronidazole is frequently used for 7 to 10 days, while nitazoxanide may be prescribed for 3 to 7 days. Treatment response should be clinically evaluated by improvement of symptoms, and in some cases, a follow-up parasitological examination may be requested several weeks after treatment completion to confirm parasite eradication. Refractory cases may require alternative or prolonged regimens.

Can this code be used in medical certificates?

Yes, code 1A35 can and should be used in medical certificates when blastocystosis is the condition that justifies absence from usual activities. Proper documentation should include diagnostic confirmation and correlation with symptoms that prevent normal performance of activities. In cases of significant gastrointestinal symptoms (frequent diarrhea, severe abdominal pain, malaise), temporary absence may be necessary, especially for professionals working with food handling or healthcare, where there is risk of transmission.

Can blastocystosis be transmitted from person to person?

Yes, transmission can occur through the fecal-oral route, through direct contact with contaminated feces or indirectly through contaminated water, food, or surfaces. Therefore, hygiene measures are fundamental to prevent transmission, including proper hand washing, especially after using the bathroom and before handling food. In collective environments such as daycare centers, schools, and institutions, rigorous hygiene measures are essential to prevent outbreaks.

Do asymptomatic patients need to be treated?

This is a controversial issue in medical literature. Most experts recommend treatment only for symptomatic patients, as many people may carry Blastocystis without developing symptoms. Exceptions may include food handlers, healthcare professionals, or people living in environments with increased transmission risk. Immunocompromised patients with identified Blastocystis should be individually evaluated regarding the need for treatment, even in the absence of significant symptoms.

Can blastocystosis cause serious complications?

In most cases, blastocystosis causes mild to moderate gastrointestinal symptoms that respond well to treatment. Serious complications are rare in immunocompetent patients. However, in immunocompromised patients or those with debilitating conditions, symptoms may be more intense and prolonged. Some studies suggest possible association between chronic Blastocystis infection and development of irritable bowel syndrome, although this relationship is still subject to research. Significant dehydration may occur in cases with profuse diarrhea, especially in young children and elderly individuals.

How to prevent Blastocystis infection?

Prevention is based on hygiene and sanitation measures: frequent and proper hand washing with water and soap, especially before meals and after using the bathroom; consumption of treated or boiled water in risk areas; careful washing of fruits and vegetables; proper cooking of food; avoiding consumption of food from questionable sources; and maintenance of adequate sanitary conditions. Travelers to areas with poor sanitation should take special care with water and food. In institutional environments, rigorous hygiene protocols should be implemented and maintained.

Conclusion: Proper coding of blastocystosis using ICD-11 code 1A35 is fundamental for accurate epidemiological recording of this intestinal parasitosis. Understanding when to apply this code, differentiating it from other protozoal infections, and properly documenting cases contributes to better epidemiological surveillance, clinical research, and quality of patient care. The diagnostic and therapeutic approach should be individualized, considering clinical presentation, epidemiological context, and patient characteristics.

External References

This article was prepared based on reliable scientific sources:

References verified on 2026-02-04

Blastocystosis

Compartir